文献速递放疗物理与技术

Unity磁共振直线加速器治疗的三维剂量验证:端口剂量学可行性研究

3D dosimetric verification of unity MR-linac treatments by portal dosimetry.
PubMed 文献 · Radiother Oncol · 2020-03-19

本研究将先前提出的Unity磁共振直线加速器二维反投影算法扩展至三维剂量重建,利用空气中及在体端口电子射野影像装置图像进行三维剂量验证。通过5例患者(2例直肠癌、2例前列腺癌、1例寡转移)治疗数据验证,与Octavius 4D系统及治疗计划系统比较,结果显示三维端口剂量学验证在治疗前和在体均可行。

要点

  • Unity磁共振直线加速器的三维端口剂量学验证在治疗前及在体均可行。
  • 与Octavius 4D系统比较,3%/2mm局部标准下平均γ值为0.52±0.10,γ通过率91.9%。
  • 治疗前验证与治疗计划系统比较,3%/2mm全局标准下平均γ值为0.52±0.04,γ通过率93.5%。

核心结论

  • 使用端口剂量学对Unity磁共振直线加速器治疗进行三维剂量验证是可行的,包括治疗前和在体验证。

研究设计与样本

  • 研究扩展了先前提出的Unity磁共振直线加速器二维反投影算法至三维剂量重建,使用空气中及在体端口电子射野影像装置图像作为输入。
  • 方法验证使用5例患者治疗数据(2例直肠癌、2例前列腺癌、1例寡转移)。

主要发现

  • 与Octavius 4D系统比较(3%, 2 mm, 局部),平均γ值为0.52±0.10,γ通过率91.9%,95%CI [85.4, 98.4],参考点剂量差ΔDRP为-0.1±1.1%。
  • 治疗前验证与治疗计划系统数据比较(3%, 2 mm, 全局),平均γ值为0.52±0.04,γ通过率93.5%,95%CI [92.4, 94.6],ΔDRP为-0.9±1.5%。
  • 在体三维验证的平均γ结果为:平均γ值0.52±0.05,γ通过率92.5%,95%CI [90.2, 94.8],ΔDRP为0.8±2.1%。

关键数值与推荐

  • 与Octavius 4D系统比较采用3%, 2 mm, 局部标准;与治疗计划系统比较采用3%, 2 mm, 全局标准。
  • 报告了参考点剂量差和γ参数(平均γ值、γ通过率及95%CI)。

临床怎么用

  • 端口剂量学可用于Unity磁共振直线加速器在线自适应治疗流程的三维剂量验证,支持治疗前和在体验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE AND BACKGROUND: 3D dosimetric verification of online adaptive workflows is essential as their complexity is unprecedented in radiation oncology. The aim of this work is to demonstrate the feasibility of back-projection portal dosimetry for 3D dosimetric verification of Unity MR-linac treatments. MATERIAL AND METHODS: An earlier presented 2D back-projection algorithm for the Unity MR-linac geometry was extended for 3D dose reconstruction and comparison against planned dose distributions. 'In-air' as well as in-vivo portal EPID images can be used as input. The method was validated using data from treatments of 5 patients (2 rectal, 2 prostate cancer and one oligo metastasis). 3D pre-treatment verification of the reference plan using 'in-air' EPID images was performed and compared against measured (with the Octavius 4D system) and planned (in the planning CT) dose distributions. In-vivo EPID dose distributions were compared to the TPS for the first three adaptations of all treatments. For all comparisons, dose difference values at the reference point and γ-parameters were reported. RESULTS: The comparison against the OCTAVIUS 4D system (3%, 2 mm, local) showed y-mean = 0.52 ± 0.10 and y-passrate = 91.9%, 95% CI [85.4, 98.4], and ΔDRP = -0.1 ± 1.1%. Pre-treatment verification against TPS data (3%, 2 mm, global) showed y-mean = 0.52 ± 0.04, y-passrate = 93.5%, 95% CI [92.4, 94.6] and ΔDRP = -0.9 ± 1.5%. The averaged y-results for the in-vivo 3D verification were y-mean = 0.52 ± 0.05, y-passrate = 92.5%, 95% CI [90.2, 94.8] and ΔDRP = 0.8 ± 2.1%. CONCLUSION: 3D dosimetric verification of Unity MR-linac treatments using portal dosimetry is feasible, pre-treatment as well as in-vivo.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Torres-Xirau I, Olaciregui-Ruiz I, Kaas J, et al. 3D dosimetric verification of unity MR-linac treatments by portal dosimetry. Radiother Oncol. 2020. PMID: 32182503. doi:10.1016/j.radonc.2020.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。